---
title: "Otezla (apremilast) in plaque psoriasis: Dosing and administration questions"
description: "Dosing and administration questions on Otezla (apremilast) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Treatment duration. Questions: What is the Otezla dose for adults with plaque psoriasis? What is the Otezla XR once-daily dose for adults? Why does Otezla treatment start with a 5-day titration? What is the Otezla dose for children with plaque psoriasis? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast) in plaque psoriasis: Dosing and administration questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)

Dosing and administration questions that apply to every indication of Otezla are on [Otezla (apremilast), all indications: Dosing and administration](https://www.evicenter.com/medical-information/otezla/dosing-and-administration).

## Dosing

<a id="otezla-adult-dose"></a>

### What is the Otezla dose for adults with plaque psoriasis?

Applies to: Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy

> “The recommended initial dosage titration from Day 1 to Day 5 is shown in Table 1. Following the 5-day 
> titration with OTEZLA, the recommended maintenance dosage is OTEZLA 30 mg twice daily or 
> OTEZLA XR 75 mg once daily taken orally starting on Day 6. This titration is intended to reduce the 
> gastrointestinal symptoms associated with initial therapy.”

Source: [OTEZLA: Prescribing information, page 3, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=3)

> “Table 1. Dosage Titration Schedule for Adult Patients with Psoriatic Arthritis, Plaque Psoriasis, or 
> Behçet’s Disease 
> OTEZLA Dosage Titration<sup>a</sup> 
> OTEZLA/OTEZLA 
> XR Maintenance 
> Dosage 
> Day 1 
> Day 2 
> Day 3 
> Day 4 
> Day 5 
> Day 6 & thereafter 
> AM 
> AM 
> PM 
> AM 
> PM 
> AM 
> PM 
> AM 
> PM 
>
> 10 mg 10 mg 10 mg 10 mg 20 mg 20 mg 20 mg 20 mg 30 mg 
> OTEZLA 30 mg BID 
> OR 
> OTEZLA XR 75 mg 
> QD 
> BID = twice daily; QD = once daily 
> <sup>a</sup> OTEZLA tablets should be used for the initial titration regardless of whether OTEZLA or OTEZLA XR will be 
> used for the maintenance dosage.”

Source: [OTEZLA: Prescribing information, page 4, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=4)

Note: In the extracted text of Table 1, the nine titration doses are listed in column order: Day 1 AM, Day 2 AM and PM, Day 3 AM and PM, Day 4 AM and PM, and Day 5 AM and PM.

<a id="otezla-xr-adult-dose"></a>

### What is the Otezla XR once-daily dose for adults?

Applies to: Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy

> “Adults with Psoriatic Arthritis, Plaque Psoriasis, or Behçet’s Disease 
> ■ See Table 1 for the initial titration schedule. Recommended maintenance 
> dosage is OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once 
> daily (2.1)”

Source: [OTEZLA: Prescribing information, page 1, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=1)

> “<sup>†</sup>Otezla tablets should be used for the initial titration regardless of whether Otezla or Otezla XR will be used for the maintenance dosage.”

Source: [OTEZLA: Otezla® (apremilast) Dosing Across Indications, captured 2026-11-13](https://www.otezlapro.com/dosing/#:~:text=tablets%20should%20be%20used%20for,used%20for%20the%20maintenance%20dosage.)

> “Whether you prescribe Otezla or Otezla XR, patients will initially titrate using Otezla”

Source: [OTEZLA: How to Start Patients on Otezla® (apremilast), captured 2026-11-13](https://www.otezlapro.com/start-today/#:~:text=Whether%20you%20prescribe%20Otezla%20or,will%20initially%20titrate%20using%20Otezla)

<a id="otezla-titration-purpose"></a>

### Why does Otezla treatment start with a 5-day titration?

> “Titration of Otezla/Otezla XR is intended to reduce the gastrointestinal symptoms associated with initiation of therapy <sup>1</sup>”

Source: [OTEZLA: Otezla® (apremilast) Dosing Across Indications, captured 2026-11-13](https://www.otezlapro.com/dosing/#:~:text=Titration%20of%20Otezla%2FOtezla%20XR%20is,associated%20with%20initiation%20of%20therapy)

> “All patients start Otezla with a titration period. <sup>1</sup> It's important to help manage expectations for patients through education on what to expect.”

Source: [OTEZLA: How to Start Patients on Otezla® (apremilast), captured 2026-11-13](https://www.otezlapro.com/start-today/#:~:text=All%20patients%20start%20Otezla%20with,education%20on%20what%20to%20expect.)

<a id="otezla-pediatric-dose"></a>

### What is the Otezla dose for children with plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “The recommended dosage for pediatric patients 6 years of age and older and weighing at least 20 kg with 
> psoriatic arthritis or moderate to severe plaque psoriasis is based on body weight. Following the 
> appropriate initial titration schedule shown in Table 2, the recommended maintenance dosage is: 
> • 
> For pediatric patients who weigh at least 50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 
> 75 mg once daily taken orally  
> • 
> For pediatric patients who weigh from 20 kg to less than 50 kg: OTEZLA 20 mg twice daily 
> taken orally  
> The initial titration is intended to reduce the gastrointestinal symptoms associated with initial therapy.”

Source: [OTEZLA: Prescribing information, page 4, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=4)

> “Table 2. Dosage Titration Schedule for Pediatric Patients 6 Years of Age and Older and Weighing 
> at Least 20 kg with Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis 
>
> OTEZLA Dosage Titration<sup>a</sup> 
> OTEZLA/OTEZLA 
> XR  
> Maintenance 
> Dosage 
> Body 
> Weight Day 1 
> Day 2 
> Day 3 
> Day 4 
> Day 5 
> Day 6 & thereafter 
>
> AM 
> AM 
> PM 
> AM 
> PM 
> AM 
> PM 
> AM 
> PM 
>
> 50 kg 
> or 
> more 
> 10 mg 10 mg 10 mg 10 mg 20 mg 20 mg 20 mg 20 mg 30 mg 
> OTEZLA 30 mg 
> BID  
> OR 
> OTEZLA XR 75 mg 
> QD 
> 20 kg 
> to less 
> 10 mg 10 mg 10 mg 10 mg 20 mg 20 mg 20 mg 20 mg 20 mg 
> OTEZLA 20 mg 
> BID”

Source: [OTEZLA: Prescribing information, page 4, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=4)

> “than 
> 50 kg 
> BID = twice daily; QD = once daily 
> <sup>a</sup> OTEZLA tablets should be used for the initial titration regardless of whether OTEZLA or OTEZLA XR will be 
> used for the maintenance dosage.”

Source: [OTEZLA: Prescribing information, page 5, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=5)

Note: In the extracted text of Table 2, each body-weight row (50 kg or more; 20 kg to less than 50 kg) lists its nine titration doses in column order (Day 1 AM through Day 5 PM), followed by the maintenance dosage. The table continues from page 4 to page 5 of the Prescribing Information.

## Treatment duration

<a id="otezla-stopping-rebound"></a>

### What happens when Otezla is stopped in plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “Severe worsening of psoriasis (rebound) occurred in 0.3% (4/1184) subjects following discontinuation of 
> treatment with OTEZLA.”

Source: [OTEZLA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=10)

> “The median time to loss of PASI-75 response among the subjects re-randomized to placebo at Week 32 
> during the Randomized Treatment Withdrawal Phase was 5.1 weeks.”

Source: [OTEZLA: Prescribing information, page 22, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=22)

Note: Both passages concern the adult moderate to severe plaque psoriasis trials (PSOR-1 and PSOR-2 in the Prescribing Information; ESTEEM 1 and ESTEEM 2 on the Otezla HCP site). The 5.1-week median concerns subjects re-randomized to placebo at Week 32 during the Randomized Treatment Withdrawal Phase.

## Related pages
- [Medical information: Otezla (apremilast): Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/specific-populations)
